Literature DB >> 17567474

Molecular mechanisms of hepatic fibrogenesis.

Christopher J Parsons1, Motoki Takashima, Richard A Rippe.   

Abstract

Liver fibrosis, a wound-healing response to a variety of chronic stimuli, is characterized by excessive deposition of extracellular matrix (ECM) proteins, of which type I collagen predominates. This alters the structure of the liver leading to organ dysfunction. The activated hepatic stellate cell (HSC) is primarily responsible for excess collagen deposition during liver fibrosis. Two important aspects are involved in mediating the fibrogenic response: first the HSC becomes directly fibrogenic by synthesizing ECM proteins; second, the activated HSC proliferates, effectively amplifying the fibrogenic response. Although the precise mechanisms responsible for HSC activation remain elusive, substantial insight is being gained into the molecular mechanisms responsible for ECM production and cell proliferation in the HSC. The activated HSC becomes responsive to both proliferative (platelet-derived growth factor) and fibrogenic (transforming growth factor-beta[TGF-beta]) cytokines. It is becoming clear that these cytokines activate both mitogen-activated protein kinase (MAPK) signaling, involving p38, and focal adhesion kinase-phosphatidylinositol 3-kinase-Akt-p70 S6 kinase (FAK-PI3K-Akt-p70(S6K)) signaling cascades. Together, these regulate the proliferative response, activating cell cycle progression as well as collagen gene expression. In addition, signaling by both TGF-beta, mediated by Smad proteins, and p38 MAPK influence collagen gene expression. Smad and p38 MAPK signaling have been found to independently and additively regulate alpha1(I) collagen gene expression by transcriptional activation while p38 MAPK, but not Smad signaling, increases alpha1(I) collagen mRNA stability, leading to increased synthesis and deposition of type I collagen. It is anticipated that by understanding the molecular mechanisms responsible for HSC proliferation and excess ECM production new therapeutic targets will be identified for the treatment of liver fibrosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17567474     DOI: 10.1111/j.1440-1746.2006.04659.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  106 in total

1.  Identification of RARRES1 as a core regulator in liver fibrosis.

Authors:  Andreas Teufel; Diana Becker; Susanne N Weber; Steven Dooley; Katja Breitkopf-Heinlein; Thorsten Maass; Katrin Hochrath; Markus Krupp; Jens U Marquardt; Martin Kolb; Bernhard Korn; Christof Niehrs; Tim Zimmermann; Patricio Godoy; Peter R Galle; Frank Lammert
Journal:  J Mol Med (Berl)       Date:  2012-06-06       Impact factor: 4.599

2.  Roles of microRNA-29a in the antifibrotic effect of farnesoid X receptor in hepatic stellate cells.

Authors:  Jiang Li; Yifei Zhang; Ramalinga Kuruba; Xiang Gao; Chandrashekhar R Gandhi; Wen Xie; Song Li
Journal:  Mol Pharmacol       Date:  2011-04-21       Impact factor: 4.436

3.  Survivin expression induced by endothelin-1 promotes myofibroblast resistance to apoptosis.

Authors:  Jeffrey C Horowitz; Iyabode O Ajayi; Priya Kulasekaran; David S Rogers; Joshua B White; Sarah K Townsend; Eric S White; Richard S Nho; Peter D R Higgins; Steven K Huang; Thomas H Sisson
Journal:  Int J Biochem Cell Biol       Date:  2011-10-25       Impact factor: 5.085

4.  Epigenetic repression of matrix metalloproteinases in myofibroblastic hepatic stellate cells through histone deacetylases 4: implication in tissue fibrosis.

Authors:  Lan Qin; Yuan-Ping Han
Journal:  Am J Pathol       Date:  2010-09-16       Impact factor: 4.307

5.  Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis.

Authors:  Ashley M Lakner; Nury M Steuerwald; Tracy L Walling; Sriparna Ghosh; Ting Li; Iain H McKillop; Mark W Russo; Herbert L Bonkovsky; Laura W Schrum
Journal:  Hepatology       Date:  2012-06-18       Impact factor: 17.425

6.  Elevation of alanine transaminase and markers of liver fibrosis after a mixed meal challenge in individuals with type 2 diabetes.

Authors:  E Y H Khoo; M C Stevenson; E Leverton; R Cross; J W Eriksson; S M Poucher; I Spendlove; P G Morris; I A Macdonald; P Mansell; G P Aithal
Journal:  Dig Dis Sci       Date:  2012-05-17       Impact factor: 3.199

7.  Imatinib mesylate improves liver regeneration and attenuates liver fibrogenesis in CCL4-treated mice.

Authors:  Wen-Ling Kuo; Ming-Chin Yu; Ju-Fang Lee; Chi-Neu Tsai; Tse-Ching Chen; Miin-Fu Chen
Journal:  J Gastrointest Surg       Date:  2011-11-09       Impact factor: 3.452

8.  Effects of Haobie Yangyin Ruanjian decoction on hepatic fibrosis induced by carbon tetrachloride in rats.

Authors:  Feng-Rui Yang; Bu-Wu Fang; Jian-Shi Lou
Journal:  World J Gastroenterol       Date:  2010-03-28       Impact factor: 5.742

9.  Protein O glycosylation regulates activation of hepatic stellate cells.

Authors:  Xiao Fan; Song Chuan; Wei Hongshan
Journal:  Inflammation       Date:  2013-12       Impact factor: 4.092

10.  Lymphocytes contribute to biliary injury and fibrosis in experimental xenobiotic-induced cholestasis.

Authors:  Nikita Joshi; Anna K Kopec; Holly Cline-Fedewa; James P Luyendyk
Journal:  Toxicology       Date:  2016-12-31       Impact factor: 4.221

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.